New pneumonia vaccine candidate enters early human testing
NCT ID NCT07428759
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new pneumococcal vaccine called PnMAPS30plus in 121 healthy adults aged 50 to 64. Participants receive a single shot of either the new vaccine or an approved one (PCV20) and are monitored for about six months. The goal is to check safety and whether the vaccine triggers a strong immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PnMAPS30plus (investigational pneumococcal vaccine)
What this could lead to
If successful, this could lead to a new vaccine option to protect against pneumococcal disease in older adults.
What could go wrong
This is an early Phase 1 trial with only 121 participants, so it's too soon to know if the vaccine works or is safe. The study focuses on safety and immune response, not on preventing pneumonia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA - BACTERIAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Norwood, South Australia, 5067, Australia
-
GSK Investigational Site
Camberwell, Victoria, 3124, Australia